SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant) Antibody from ABBEXA LTD
Search, find, compare suppliers for anti-SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant) |
| Clone | monoclonal |
| Host Species | Human |
| Reactive Species | n/a |
| Isotype | IgG1 |
| Format | Protein A purified |
| Size | 50 µg, 100 µg |
| Concentration | 1 mg/ml |
| Applications | n/a |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD (Delta B.1.617.2 Variant) Neutralizing Antibody is a recombinant Human Monoclonal Antibody against SARS-CoV-2/COVID-19 Spike Protein RBD (Delta B.1.617.2 Variant). The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action. The B.1.617.2 (Delta) variant was first identified in India. It contains the L452R and T478K mutations, which appear to increase viral infectivity compared with other variants. |
| Immunogen | n/a |
| Other Names | Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2, COVID-19, 2019-nCoV, 2019 novel coronavirus, COVID19, SARS-CoV-2 Spike S1 (RBD), SARS-CoV-2 Spike S1 RBD (Receptor-Binding Domain) Protein, SARS-CoV-2 Spike Protein RBD (India B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 India Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 Indian Variant), SARS-CoV-2 S1 Protein RBD L452R and T478K Mutations, SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (Delta Variant), Severe Acute Respiratory Syndrome Coronavirus 2, Severe Acute Respiratory Syndrome Coronavirus 2, Severe Acute Respiratory Syndrome Coronavirus 2, Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2, SARS-CoV-2, SARS-CoV-2, SARS-CoV-2, COVID-19, COVID-19, COVID-19, COVID-19, 2019-nCoV, 2019-nCoV, 2019-nCoV, 2019-nCoV, 2019 novel coronavirus, 2019 novel coronavirus, 2019 novel coronavirus, 2019 novel coronavirus, COVID19, COVID19, COVID19, COVID19, SARS-CoV-2 Spike S1 (RBD), SARS-CoV-2 Spike S1 (RBD), SARS-CoV-2 Spike S1 (RBD), SARS-CoV-2 Spike S1 (RBD), SARS-CoV-2 Spike S1 RBD (Receptor-Binding Domain) Protein, SARS-CoV-2 Spike S1 RBD (Receptor-Binding Domain) Protein, SARS-CoV-2 Spike S1 RBD (Receptor-Binding Domain) Protein, SARS-CoV-2 Spike S1 RBD (Receptor-Binding Domain) Protein, SARS-CoV-2 Spike Protein RBD (India B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (India B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (India B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (India B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 India Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 India Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 India Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 India Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 Indian Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 Indian Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 Indian Variant), SARS-CoV-2 Spike Protein RBD (B.1.617.2 Indian Variant), SARS-CoV-2 S1 Protein RBD L452R and T478K Mutations, SARS-CoV-2 S1 Protein RBD L452R and T478K Mutations, SARS-CoV-2 S1 Protein RBD L452R and T478K Mutations, SARS-CoV-2 S1 Protein RBD L452R and T478K Mutations, SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant), SARS-CoV-2 Spike Protein RBD (Delta Variant), SARS-CoV-2 Spike Protein RBD (Delta Variant), SARS-CoV-2 Spike Protein RBD (Delta Variant), SARS-CoV-2 Spike Protein RBD (Delta Variant) |
| Gene, Accession # | n/a |
| Catalog # | abx376487 |
| Price | please inquire |
| Order / More Info | SARS-CoV-2 Spike Protein RBD (Delta B.1.617.2 Variant) Antibody from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Antibodies